Newsummit Acquires Novel HCV Treatment from UK's MRC Technology

Shanghai Newsummit Biopharma in-licensed rights to a novel antibody targeting Hepatitis C virus from MRC Technology of the UK. Newsummit, a CRO with expertise in process development and clinical studies, is a unit of Zhejiang Yatai Pharma, an infectious disease company. Newsummit has established a collaborative CRO network for other services. MRC said the novel molecule was humanized by MRC Tech scientists, and originated in the laboratory of Prof. Arvind Patel, of the MRC-University of Glasgow Centre for Virus Research. Financial details were not disclosed. More details.... Stock Symbol: (SHZ: 002370) Share this with colleagues: // //